Acyclovir Lauriad(®): a muco-adhesive buccal tablet for the treatment of recurrent herpes labialis.The treatment of recurrent herpes labialis remains a challenge in the 21st century.  Acyclovir Lauriad(®) is a new topical agent that was approved by the US FDA in 2013 for the treatment of recurrent herpes labialis, which affects approximately 20-40% of the population worldwide. 
Acyclovir Lauriad(®)
Utilizing Lauriad(®) technology, a biologically active compound traverses the mucous membrane to deliver a high concentration of acyclovir directly to the site of the herpes simplex virus infection. 
Lauriad(®) technology
Acyclovir Lauriad(®) is a new topical agent that was approved by the US FDA in 2013 for the treatment of recurrent herpes labialis, which affects approximately 20-40% of the population worldwide. 
US FDA